Back
Myriad Genetics 10K Form
Sell
21
MYGN
Myriad Genetics
Last Price:
$13.35
Seasonality Move:
14.35%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-08 | 10Q | MYGN/Myriad Genetics Quarterly |
2023-11-07 | 10Q | MYGN/Myriad Genetics Quarterly |
2023-08-04 | 10Q | MYGN/Myriad Genetics Quarterly |
2023-05-04 | 10Q | MYGN/Myriad Genetics Quarterly |
2022-11-02 | 10Q | MYGN/Myriad Genetics Quarterly |
2022-08-05 | 10Q | MYGN/Myriad Genetics Quarterly |
Receive MYGN News And Ratings
See the #1 stock for the next 7 days that we like better than MYGN
MYGN Financial Statistics
Sales & Book Value
Annual Sales: | $753.2M |
---|---|
Cash Flow: | $-5.6M |
Price / Cash Flow: | 0 |
Annual Sales: | $8.04 |
Price / Book: | 1.66 |
Profitability
EPS (TTM): | -1.30000 |
---|---|
Net Income (TTM): | $-116M |
Gross Margin: | $517M |
Return on Equity: | -15.68% |
Return on Assets: | -10.41% |
Myriad Genetics Earnings Forecast
Key Myriad Genetics Financial Ratios
-
The Gross Profit Margin over the past 28 years for MYGN is 68.64%.
-
The Selling, General & Administrative Expenses for MYGN have been equal to 76.06% of Gross Profit Margin.
-
The Research & Development expenses have been 11.78% of Revenue.
-
The Interest Expense is -1.10% of Operating Income.
-
The Net Earning history of MYGN is -34.96% of Total Revenues.
-
Per Share Earnings over the last 28 years have been positive in 14 years.
Myriad Genetics Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | MYGN |
CUSIP: | 62855J |
Website: | myriad.com |
Debt
Debt-to-Equity Ratio: | 0.05 |
---|---|
Current Ratio: | 1.9 |
Quick Ratio: | 1.46 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 116.91 |
MYGN Technical Analysis vs Fundamental Analysis
Sell
21
Myriad Genetics (MYGN)
is a Sell
Is Myriad Genetics a Buy or a Sell?
-
Myriad Genetics stock is rated a SellThe current Myriad Genetics [MYGN] share price is $13.36. The Score for MYGN is 21, which is 58% below its historic median score of 50, and infers higher risk than normal.